Clinical research Coordinator
ICH E6 R3 GCP guidelines 2025 2026 updates
ICH E6 R2 GCP core principles summary CRC clinical research coordinator
ICH E6 R3 principles GCP
| # | Principle | What It Means in Practice |
|---|---|---|
| 1 | Ethical conduct per Declaration of Helsinki | All research must be ethically sound; IRB/IEC approval is mandatory before any trial activity |
| 2 | Benefits justify risks | Risk-benefit ratio must favor participants; documented in the protocol |
| 3 | Participant rights, safety, and well-being take priority | Always supersedes science or sponsor interests |
| 4 | Available nonclinical and clinical info supports the trial | Investigational products must have adequate prior data |
| 5 | Scientific soundness of the protocol | Protocol must be clear, detailed, and statistically valid |
| 6 | Compliance with protocol | Follow the protocol as approved; deviations must be documented and reported |
| 7 | Medical care of participants | A qualified physician must be responsible for medical decisions |
| 8 | Qualified staff | All staff must be trained and qualified for their roles |
| 9 | Freely given informed consent | Obtained before any trial procedure; must be ongoing |
| 10 | Data recording and reporting | All data must be recorded accurately and verifiably |
| 11 | Confidentiality of records | Participant identifiable information must be protected |
| 12 | Investigational product manufacturing per GMP | Product quality and handling per Good Manufacturing Practice |
| 13 | Quality systems for every aspect of the trial | Sponsor must implement quality assurance and quality control |
| # | Principle | Key Change from R2 |
|---|---|---|
| 1 | Ethical conduct | Unchanged - Declaration of Helsinki remains the foundation |
| 2 | Rights, safety, and well-being | Unchanged - still the top priority |
| 3 | Benefits justify risks | Unchanged |
| 4 | Qualified staff & medical oversight | Consolidates R2 principles 7 & 8 |
| 5 | Informed consent | Unchanged in intent; updated to reflect eConsent and remote participation |
| 6 | Quality by Design (NEW) | Quality must be built into trial design upfront, not checked for at the end. Focus on what matters most to trial outcomes |
| 7 | Proportionality (NEW) | Oversight and administrative burden should match the actual risk level. Low-intervention trials need less burden than first-in-human studies |
| 8 | Protocol compliance | Deviation handling clarified - safety always takes precedence; root cause and corrective action required |
| 9 | Data integrity & ALCOA++ | Expanded to cover all record formats including metadata and audit trails |
| 10 | Roles and responsibilities | Clearer delineation of sponsor, investigator, CRO, and CRC duties |
| 11 | Confidentiality | Unchanged in intent; updated for modern data protection laws (GDPR, HIPAA) |
| Letter | Standard |
|---|---|
| A | Attributable - who collected it and when |
| L | Legible - readable and permanent |
| C | Contemporaneous - recorded at time of observation |
| O | Original - first capture of data, not a copy |
| A | Accurate - correct and precise |
| +C | Complete |
| +C | Consistent |
| +E | Enduring - data preserved for required retention period |
| +A | Available - accessible for review and audit |
| Feature | E6(R2) | E6(R3) |
|---|---|---|
| Number of principles | 13 | 11 |
| Quality approach | Reactive QC | Proactive Quality by Design |
| Risk approach | General | Proportionality built in |
| Monitoring | Risk-based monitoring encouraged | RBM and centralized monitoring normalized |
| Decentralized trials | Not addressed | Explicitly accommodated |
| Data formats | Primarily paper/EDC | All formats including eSource, eConsent, wearables |
| Informed consent | Traditional | eConsent explicitly recognized |